Endonovo Therapeutics Files Patent on Bioelectronic Technology, Devices and Therapies

LOS ANGELES, CA--(Marketwired - Sep 2, 2014) - Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of novel cell-free therapies, announced today that it has filed a patent on bioelectronic technologies, devices and therapies (the "Technology").

The Technology, which was originally developed in conjunction with NASA during the space program for the expansion of adult stem cells, is now being developed by Endonovo to directly treat injuries and diseases.

Endonovo's Technology is part of the emerging field of bioelectronic medicine, which brings forward a revolutionary new way of treating human illness and disease using electrical signals transmitted through nerves in the human body. Healthcare innovator GlaxoSmithKline (GSK) and the Defense Advanced Research Projects Agency (DARPA) have each announced initiatives to create miniature implantable bioelectronic devices that can analyze and modify electrical signals in nerves to treat disease and illnesses.

Unlike GSK and DARPA, Endonovo is developing non-implantable bioelectronic devices that use a Time-Varying Electromagnetic Field (TVEMF) to induce an electrical field/signal in a targeted tissue to treat multiple inflammatory conditions and diseases, including fulminant liver failure, acute kidney injury, and acute myocardial infarction.

Endonovo's bioelectronic Technology possesses many potential competitive advantages over cell therapies and biologics currently under development, including increased safety, true scalability, lower costs and a much shorter time to market for therapies.

"We are thrilled to be at the forefront of the revolutionary field of bioelectronics," stated Endonovo CEO, Alan Collier. "We are developing non-invasive bioelectronic devices that can be brought to market within the decade that hold the potential to transform the way many injuries and inflammatory diseases are treated."

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is an innovative developer of non-invasive, bioelectronic devices and off-the-shelf, cell free regenerative products. Endonovo's core technologies, Time-Varying Electromagnetic Fields (TVEMF), were originally developed in conjunction with the National Aeronautics and Space Administration (NASA) during the space program to expand adult stem cells and are now being developed by the Company as a novel approach to treating injuries and diseases.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.